CYP19A1 and breast cancer: In preclinical breast cancer models, HDACi have been shown to induce estrogen receptor-alpha (ERα) and aromatase expression in ERα-negative cells, leading to increased sensitivity to tamoxifen and aromatase inhibitor letrozole [155,156,157].